SFX-01 After Subarachnoid Haemorrhage
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Sulforafan (Primary)
- Indications Subarachnoid haemorrhage
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SAS
- Sponsors Evgen Pharma
- 23 Nov 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 23 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
- 23 Nov 2017 Status changed from recruiting to active, no longer recruiting.